Treatment of HER-2/neu Overexpressing Breast Cancer Xenograft Models With Trastuzumab (Herceptin) and Gefitinib (ZD1839): Drug Combination Effects on Tumor Growth, HER-2/neu and Epidermal Growth Factor Receptor Expression, and Viable Hypoxic Cell Fraction

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-03-0244
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Inhibition of Cell Growth and Induction of Apoptosis byAntrodia Camphoratain HER-2/neu-Overexpressing Breast Cancer Cells Through the Induction of ROS, Depletion of HER-2/neu, and Disruption of the PI3K/Akt Signaling Pathway

Evidence-based Complementary and Alternative Medicine
Alternative MedicineComplementary
2012English

Impact of Polysomy 17 on HER-2/neu Immunohistochemistry in Breast Carcinomas Without HER-2/neu Gene Amplification

Journal of Molecular Diagnostics
Forensic MedicinePathologyMolecular Medicine
2003English

Hormone Receptors, Her-2/Neu and Chromosomal Aberrations in Breast Cancer

Medical Journal Armed Forces India
Medicine
2008English

Amplification of Her-2/Neu Gene in Her-2/Neu-Overexpressing and -Nonexpressing Breast Carcinomas and Their Synchronous Benign, Premalignant, and Metastatic Lesions Detected by FISH in Archival Material

Modern Pathology
Forensic MedicinePathology
2002English

Use of the Anti HER-2/neu Antibody Herceptin in the Treatment of Human Breast Cancer: Biological Rationale and Clinical Results

Breast Cancer Research
Cancer ResearchOncology
2000English

Booster Immunizations With DNA Plasmids Encoding HER-2/neu Prevent Spontaneous Mammary Cancer in HER-2/neu Transgenic Mice Over Life Span

Scientific Reports
Multidisciplinary
2017English

HER-2/neu Expression in Cervical Intraepithelial Neoplasia and Cervical Carcinoma

International Journal of Biomedical and Advance Research
2015English

Chemosensitization of HER-2/neu-overexpressing Human Breast Cancer Cells to Paclitaxel (Taxol) by Adenovirus Type 5 E1A

Oncogene
Cancer ResearchGeneticsMolecular Biology
1997English

Substituting Adjuvant Trastuzumab Emtansine for Herceptin Improves Survival in Patients With Human Epidermal Growth Factor Receptor 2–positive Breast Cancer

Cancer
Cancer ResearchOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy